Cite

HARVARD Citation

    Eyre, T. et al. (2019). A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer. 125 (1), pp. 99-108. [Online]. 
  
Back to record